Results 331 to 340 of about 14,739,736 (367)
Some of the next articles are maybe not open access.
Standardization of Factor IX: Standards for "Purified" Factor IX Concentrates
Thrombosis and Haemostasis, 1991SummaryAn international collaborative study was carried out to determine the suitability of the current WHO II-IX-X concentrate standard, 84/681, for assigning potency to the more highly purified factor IX concentrates. Three Coagulation Factor IX (Human) preparations and one Factor IX Complex preparation were assayed by the one stage method against ...
M A, Lamb, W A, Fricke, S C, Rastogi
openaire +2 more sources
Scandinavian Journal of Haematology, 1977
Fractionation technology has made Factor IX concentrates available. In addition to a very high incidence of hepatitis, thrombosis is being recognized as a consequence of their use. Contradictory reports exist in the literature as to the incidence of thrombotic events.
openaire +2 more sources
Fractionation technology has made Factor IX concentrates available. In addition to a very high incidence of hepatitis, thrombosis is being recognized as a consequence of their use. Contradictory reports exist in the literature as to the incidence of thrombotic events.
openaire +2 more sources
Immune Reactive Factor IX in Acquired Factor IX Deficiency
Thrombosis and Haemostasis, 1972SummaryFactor IX-antibody-neutralizing material has been estimated in plasmas of patients with acquired factor IX deficiency. In patients with liver cirrhosis and patients who had been treated with L-Asparaginase the plasma neutralized an amount of antibody expected from the biological activity. In patients treated with phenprocoumon and in one patient
openaire +2 more sources
Factor IX complex for the correction of traumatic coagulopathy
Journal of Trauma and Acute Care Surgery, 2012BACKGROUND: Damage control resuscitation advocates correction of coagulopathy; however, options are limited and expensive. The use of prothrombin complex concentrate (PCC), also known as factor IX complex, can quickly accelerate reversal of coagulopathy ...
B. Joseph +9 more
semanticscholar +1 more source
Monoclonal antibodies to factor IX: Characterization and use in immunoassays for factor IX
Thrombosis Research, 1984Monoclonal antibodies to factor IX have been characterized for potential use in purification of factor IX and for analysis of factor IX abnormalities seen in hemophilia B and other conditions. The properties of six monoclonal antibodies to factor IX are summarized in this report.
K J, Smith, K, Ono
openaire +2 more sources
Suppression of Factor IX Antibody in Hemophilia B by Factor IX and Cyclophosphamide
Annals of Internal Medicine, 1973Abstract Two patients with severe hemophilia B complicated by inhibitors of factor IX (equivalent to 0.6 and 4 to 12 units per millilitre plasma, respectively) are described.
I M, Nilsson, U, Hedner, G, Björlin
openaire +2 more sources
The isolation of prothrombin, factor IX and factor X from human factor IX concentrates
Thrombosis Research, 1984A relatively simple and reproducible procedure is described for the isolation of functionally and electrophoretically homogeneous prothrombin, factor IX and factor X from clinical Factor IX Concentrates. The procedure involves ammonium sulphate fractionation; then chromatography on DEAE-Sephadex A50, dextran sulphate-Sepharose and heparin-Sepharose ...
G J, Modi, M A, Blajchman, F A, Ofosu
openaire +2 more sources
Pharmacokinetics of factor VIII and factor IX
Haemophilia, 2003Summary. A survey of principal pharmacokinetic (PK) studies on factor VIII (FVIII) and factor IX (FIX) plasma‐ and rDNA‐derived concentrates, analysed by means of the PKRD program, has been performed. Notwithstanding the accurate definition of the study design, released in 1991 by the Scientific and Standardization Committee of the International ...
openaire +2 more sources
Activation of Factor IX by Factor XIa
Trends in Cardiovascular Medicine, 2000Blood coagulation factor IX is activated during hemostasis by two distinct mechanisms. Activation through factor VIIa/tissue factor occurs early in the course of fibrin clot formation. Activation by factor XIa appears to be important for maintaining the integrity of the clot over time.
openaire +2 more sources